Ser170
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser170  -  GCK (human)

Site Information
ASVAKRRsFIGtPYW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 7997228
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , lung cancer ( 4 , 5 , 6 , 7 ) , non-small cell lung cancer ( 4 , 5 , 6 , 7 ) , non-small cell lung adenocarcinoma ( 4 , 5 , 6 , 7 ) , non-small cell large cell lung carcinoma ( 5 , 6 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 4 ) , breast ( 2 , 3 ) , DMS153 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 6 ) , HEK293-A (epithelial) ( 1 ) , Jurkat (T lymphocyte) ( 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , lung ( 4 , 5 , 6 , 7 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1355 (pulmonary) ( 4 ) , NCI-H1437 (pulmonary) ( 7 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1792 (pulmonary) ( 4 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H2073 (pulmonary) ( 7 ) , NCI-H209 (pulmonary) ( 7 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H23 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 6 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 5 ) , NCI-H661 (pulmonary) ( 6 ) , NCI-H838 (pulmonary) ( 7 )

Upstream Regulation
Regulatory protein:
striatin 4 (human) ( 1 )
Putative in vivo kinases:
GCK (human) ( 1 )
Treatments:
amino_acid_starvation ( 1 ) , glucose_starvation ( 1 ) , HBSS ( 1 ) , serum_starvation ( 1 ) , TL4-12 ( 1 )

Downstream Regulation
Effects of modification on GCK:
enzymatic activity, induced ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
autophagy, induced ( 1 ) , carcinogenesis, induced ( 1 )

References 

1

Seo G, et al. (2023) The Hippo pathway noncanonically drives autophagy and cell survival in response to energy stress. Mol Cell 83, 3155-3170.e8
37595580   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Guo A (2012) CST Curation Set: 13981; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

9

Guo A (2012) CST Curation Set: 13982; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

10

Mulhern D (2012) CST Curation Set: 13939; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

11

Mulhern D (2012) CST Curation Set: 13828; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

12

Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

13

Mulhern D (2011) CST Curation Set: 13110; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -;
Curated Info

14

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

15

Guo A (2011) CST Curation Set: 11893; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

16

Possemato A (2010) CST Curation Set: 9725; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.